Article

Ocular pulse amplitude test detects stroke risk

Ophthalmologists someday may perform ocular pulse amplitude (OPA) tests during routine eye exams to identify patients who are at high risk for stroke, according to researchers at the University of Zurich.

Zurich, Switzerland-Ophthalmologists someday may perform ocular pulse amplitude (OPA) tests during routine eye exams to identify patients who are at high risk for stroke, according to researchers at the University of Zurich, Switzerland.

The test can reliably detect symptomless carotid artery stenosis (CAS), a condition that is a known risk factor for stroke. Researchers found that patients who had the lowest OPA scores also had the most seriously blocked arteries. The study is published in the June issue of Ophthalmology.

The investigators used a dynamic contour tonometer to check the OPA of 67 patients who were assumed to have CAS. After measuring the IOP levels, the tonometer computes the patient’s OPA score by finding the difference between the IOP levels that occur during the systolic and diastolic heartbeats.

When blood flow to the eye is blocked by CAS, not much difference exists between the two pressure levels, so the OPA score is low. The researchers used ultrasound exams to corroborate that each study participant had CAS and to detail the severity of his or her blockage.

“Our results show that OPA is a reliable, safe screening test for CAS,” said lead researcher Pascal Bruno Knecht, MD. “We recommend further study to confirm the value of using OPA to detect and assess the severity of CAS and to define its use in stroke prevention.”

Ophthalmologists already using a dynamic contour tonometer to screen for glaucoma could very efficiently perform the OPA test during a standard eye exam, according to the researchers, who added that this type of tonometer is not widely used in the United States, although it is in Europe.

The researchers say that other than CAS, very few diseases could cause low OPA scores and that an ophthalmologist could easily rule out these other diseases during an eye exam.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.